Skip to content
PreclinicalResearch compoundModerate evidence

GTS‑21

Experimental nootropic developed for the thinking problems of schizophrenia; not proven in people, and the results were inconsistent.

NootropicCholinergicCholinergicMemoryAcetylcholinenoo.affects.neuroprotectionnoo.affects.anti-inflammatory

Pharmacology

ClassCholinergic · Memory
Primary targetAlpha-7 nicotinic (a7 nAChR) partial agonism
Targets4 receptor targets
Half-lifeShort, on the order of a few hours; its active metabolite is 4-OH-GTS-21 (this short PK limited clinical efficacy)
OnsetOral dosing; cognitive effects in human trials appeared within hours of a dose
EvidenceModerate evidence
Affected systemsAcetylcholinenoo.affects.neuroprotectionnoo.affects.anti-inflammatory

Contents

DETAILED OVERVIEW

What is GTS-21?

GTS-21 (also known as DMXB-A) is an experimental compound, a synthetic derivative of anabaseine, a marine toxin. It is not approved as a medicine anywhere and exists only as a research compound. It was originally developed to improve the attention and thinking problems that go with schizophrenia.

It partly switches on one of the brain's nicotinic receptors (alpha-7), which helps regulate attention, working memory and the filtering of incoming stimuli. Small, early-phase studies were done in healthy volunteers and in people with schizophrenia. In schizophrenia it improved this filtering, but its effect on thinking was inconsistent, partly because the substance breaks down quickly and its blood level fluctuates. Its benefit in people is therefore not proven; in animals it improved learning and memory. It can cause nausea and headache, its long-term safety in humans is unclear, and its safety in pregnancy and breastfeeding has not been established.

Mechanism

α7 nAChR partial agonist

Evidence

Phase 2 human trials (not approved)

Legal status

Experimental, unapproved drug

Receptor profile

  • Alpha-7 nicotinic acetylcholine receptor (α7 nAChR)Strong
  • Glutamatergic / dopaminergic signaling (indirect)Moderate
  • Cholinergic anti-inflammatory pathway (NF-κB suppression)Moderate
  • Alpha-4-beta-2 nicotinic receptor (weak antagonism)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 5

  • Gastrointestinal complaints: nausea, abdominal discomfort, occasional vomiting at higher doses
  • Headache and dizziness reported in human trials
  • Short half-life and an active metabolite (4-OH-GTS-21) cause fluctuating plasma levels and effect
  • Efficacy was inconsistent across phase 2 trials: cognitive benefit was not always confirmed
  • Long-term safety in humans is unclear; there is no approved therapeutic use

Contraindications · 4

  • Pregnancy and breastfeeding: safety not established, avoid
  • Unapproved experimental compound; not recommended without clinical supervision
  • Active gastrointestinal disease: nausea and GI effects may aggravate it
  • Unknown interaction profile: caution with cholinergic and psychoactive agents

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

GTS-21 is an experimental compound, a synthetic relative of a marine-organism toxin, that targets a specific brain receptor involved in attention and working memory. In small, early-stage human trials it improved sensory filtering in people with schizophrenia, and in animal studies it showed learning and memory benefits along with nerve-protective effects. This is fundamentally a research-stage substance with a moderate amount of early human data, not an established, widely used nootropic.

Telegram

Have a question about GTS‑21?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC19H20N2O2
UpdatedOctober 13, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 13, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.